Ajinomoto Co., Inc.

Ajinomoto Co., Inc.

AJINY
Ajinomoto Co., Inc.US flagOther OTC
28.19
USD
-0.11
- -
14.38BMarket Cap
Ajinomoto Co., Inc.
AJINY
(Other OTC)

Recent

price

28.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
865.32
878.54
756.92
774.77
850.22
977.3
954.21
980.44
1,005.86
1,003.42
976.99
1,058.1
1,271.29
691.5
759.81
- -
729.55
Revenue per Share
21.78
30.64
37.17
34.33
39.27
60.62
46.4
52.88
26.81
17.18
54.18
69.71
87.99
41.86
34.88
- -
39.49
Basic EPS, GAAP
78.26
65.78
64.13
46.93
89.01
61.95
68.88
105.03
102.39
97.16
142.7
127.68
105.68
77.76
100.73
- -
80.53
Free Cash Flow per Basic Share
8
8.07
8.15
10.13
10.01
13.59
15.08
15.01
16.66
16.01
15.98
25.11
29.59
18.45
19.43
- -
18.68
Dividend per Share
353.99
384.92
432.16
473.81
487.54
537.82
581.27
623.41
609.46
596.69
627.25
640.87
684.86
354.41
332.79
- -
748.25
Book Value per Share
419.01
433.63
501.83
491.22
514.09
464.57
466.65
481.15
477.02
394.84
455.57
526.2
621.97
310.75
299.43
- -
589.87
Tangible Book Value per Share
1,396
1,363
1,301
1,228
1,184
1,176
1,144
1,137
1,108
1,096
1,097
1,086
1,069
2,081
2,014
973
1,030
Basic Weighted Avg Shares
1,207,695
1,197,313
984,967
951,359
1,006,630
1,149,427
1,091,195
1,114,784
1,114,308
1,100,039
1,071,453
1,149,370
1,359,115
1,439,231
1,530,556
- -
751,227
Sales/Revenue/Turnover
5.74
6.06
7.23
6.5
7.4
8.57
7.43
6.7
4.86
4.66
9.32
10.75
10.64
9.86
7.03
- -
9.4
Operating Margin (%)
54,330
48,220
44,728
47,335
45,577
50,852
46,273
51,783
52,485
61,986
63,045
66,234
71,820
78,298
86,461
- -
40,596
Depreciation Expense
30,400
41,754
48,373
42,159
46,495
71,292
53,065
60,124
29,698
18,837
59,416
75,725
94,065
87,121
70,272
- -
40,664
Net Income, GAAP
25.95
34
45.36
31.66
29.95
20.89
25.05
18.97
32.35
41.77
32.59
34.49
28.47
28.17
25.44
- -
29.4
Effective Tax Rate (%)
2.52
3.49
4.91
4.43
4.62
6.2
4.86
5.39
2.67
1.71
5.55
6.59
6.92
6.05
4.59
- -
5.41
Profit Margin (%)
298,091
302,920
330,533
312,680
231,696
374,129
312,651
324,049
299,411
203,335
248,830
256,788
275,893
208,063
316,710
- -
-333,881
Working Capital
109,271
104,837
81,434
104,428
74,073
243,226
298,964
309,711
306,636
273,685
291,519
271,281
239,244
254,224
416,207
- -
442,401
LT Debt
650,291
650,158
691,710
655,505
725,331
680,727
690,673
720,613
685,960
592,070
667,846
739,744
822,968
884,448
813,273
- -
833,266
Total Equity
6.46
6.08
4.82
5.17
5.96
8.18
6.1
5.76
3.5
3
6.76
7.74
9.44
8.28
6.12
- -
3.82
Return on Invested Capital (%)
4.03
5.48
5.96
4.75
4.74
7.25
4.34
5.29
2.28
1.25
5.31
7.18
9.23
6.98
5.78
- -
2.76
Return on Capital (%)
6.28
8.2
8.9
7.37
8.02
11.79
8.18
8.75
4.29
2.83
8.85
10.94
13.17
11.85
9.98
- -
5.31
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
188,270
- -
48,972
LT Borrowings
254,224
- -
442,401
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,025
- -
1,008
Market Capitalization
2,939,710
2,930,556
2,838,842

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
194,187
- -
196,124
Accounts Receivable, Net
185,564
- -
175,884
Inventories
287,122
- -
303,879
Total Current Liabilities
501,569
- -
333,881
Payables & Accruals
- -
- -
- -
ST Debt
188,270
- -
48,972
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
339,521
348,482
379,641
371,586
1,439,231
2025
- -
- -
- -
- -
1,530,556
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25.89
18.5
29.97
- -
41.86
2025
- -
- -
- -
- -
34.88
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
17.78
0.46
18.44
- -
18.45
2025
- -
- -
- -
- -
19.43
2026
- -
- -
- -
- -
- -
Business
Ajinomoto Co., Inc. is a Japan-based multinational corporation primarily engaged in the food and healthcare industries. Founded in 1909 and headquartered in Chuo-ku, Tokyo, Ajinomoto operates globally, offering a diverse portfolio of products across three main business segments: Seasonings and Foods; Frozen Foods; and Healthcare and Other businesses. The Seasonings and Foods segment provides seasonings, processed foods, nutritional products, solutions, and ingredients including brands like AJIPHASE® and AJICAP®. The Frozen Foods segment offers a wide range of frozen meals and food products. The Healthcare and Other segment supplies pharmaceutical- and food-use amino acids, biopharmaceutical services, functional materials, and gene therapies. Recent major changes include Ajinomoto’s strategic acquisitions and partnerships aimed at expanding its presence in sustainable and next-generation protein solutions. In 2025, Ajinomoto entered a strategic partnership with v2food and acquired Daring Foods to accelerate the development and global scaling of plant-based protein products, leveraging v2food’s advanced protein technology and Daring’s existing US market footprint. Additionally, Ajinomoto sold its entire equity stake in Ajinomoto Althea, a US-based aseptic fill-finish contract development and manufacturing organization (CDMO), to focus more on high-value-added business models based on proprietary technologies. The company also acquired Forge Biologics for $620 million to strengthen its biopharmaceutical service capabilities, particularly in gene therapy. Furthermore, Ajinomoto Health & Nutrition North America launched new product platforms addressing sodium reduction, taste enhancement, and formulation efficiency in 2025. Ajinomoto operates extensively across Japan, Asia, the Americas, and Europe, targeting both consumer and industrial customers in the food, health, and biotech fields. The company continues to leverage its historical expertise in amino acid technology to innovate in nutrition, pharmaceuticals, and sustainable food systems globally and pursues growth through its global network and investments in next-generation food and healthcare technologies. Ajinomoto employs approximately 35,000 people worldwide and reported revenue exceeding 1.5 trillion yen in recent fiscal years. Its comprehensive offerings serve diverse markets from everyday consumer food products to specialized healthcare and biopharma solutions.

Company News

APIChatGPT
  • AI Needs Ajinomoto's Film, But Its CEO Won't Raise Prices Just Because

  • Ajinomoto Q4 Earnings: The Good And The Bad

  • Analyzing J. M. Smucker (NYSE:SJM) and Ajinomoto (OTCMKTS:AJINY)

  • Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

  • Is MSG Maker Ajinomoto Sitting on an AI Goldmine? This Investor Thinks So

  • Critical Contrast: Ajinomoto (OTCMKTS:AJINY) vs. J. M. Smucker (NYSE:SJM)

  • Palliser Capital Publishes Value Enhancement Plan for Ajinomoto

  • Ajinomoto Co., Inc. (AJINY) Q3 2026 Earnings Call Transcript

  • Ajinomoto Co., Inc. (AJINY) Q2 2026 Earnings Call Transcript

  • Ajinomoto Co., Inc. - Special Call

  • Ajinomoto Co., Inc. (AJINY) Q1 2026 Earnings Call Transcript

  • Ajinomoto Co., Inc. (AJINY) Q4 2025 Earnings Call Transcript

  • L-Phenylalanine Market Insights and Forecast to 2030 Featuring Profiles (SWOT, Sales, Prices) of Key Players - Evonik, Ajinomoto, Daesang, and Wuxi Jinghai Amino Acid Co.

  • L-Alanyl-L-Glutamine Market Report 2025: Includes Insights Into the Sales, Revenue, Price, Gross Margin & SWOT of Kyowa Hakko, Ajinomoto, and Evonik

  • PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

  • Ajinomoto Co., Inc. (AJINY) Q2 2024 Earnings Call Transcript

  • Ajinomoto Co., Inc. (AJINY) Q1 2024 Earnings Call Transcript

  • Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

  • Essential Japanese Semi Companies For The Reshoring Age

  • Ajinomoto: Food, Biotech, And Semis All-In-One